Catechol-O-methyltransferase
Nguồn tham khảo

↑  Flower R, Rang HP, Dale MM, Ritter JM (2007). “Figure 11-4”. Rang & Dale's pharmacology (ấn bản thứ 6). Edinburgh: Churchill Livingstone. ISBN 978-0-443-06911-6.
↑  Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2011). “Figure 14.4”. Rang & Dale's Pharmacology. Student consult (ấn bản thứ 7). Elsevier Health Sciences. ISBN 978-0-7020-4504-2.
↑  “Test ID: COMT: Catechol-O-Methyltransferase Genotype”. www.mayomedicallaboratories.com. Mayo Clinic: Mayo Medical Laboratories. Bản gốc lưu trữ ngày 18 tháng 9 năm 2008. Truy cập ngày 16 tháng 11 năm 2016.
↑  Grossman MH, Emanuel BS, Budarf ML (tháng 4 năm 1992). “Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1----q11.2”. Genomics. 12 (4): 822–5. doi:10.1016/0888-7543(92)90316-K. PMID 1572656.
↑  Tai CH, Wu RM (tháng 2 năm 2002). “Catechol-O-methyltransferase and Parkinson's disease”. Acta Medica Okayama. 56 (1): 1–6. PMID 11873938.
↑  Axelrod J (tháng 8 năm 1957). “O-Methylation of Epinephrine and Other Catechols in vitro and in vivo”. Science. 126 (3270): 400–1. doi:10.1126/science.126.3270.400. PMID 13467217.
↑  Ruottinen HM, Rinne UK (tháng 11 năm 1998). “COMT inhibition in the treatment of Parkinson's disease”. Journal of Neurology. 245 (11 Suppl 3): P25–34. doi:10.1007/PL00007743. PMID 9808337.

     Goetz CG (tháng 5 năm 1998). “Influence of COMT inhibition on levodopa pharmacology and therapy”. Neurology. 50 (5 Suppl 5): S26–30. doi:10.1212/WNL.50.5_Suppl_5.S26. PMID 9591519.
↑  Brodal P (2016). “Chapter 5: Neurotransmitters and their receptors”. The Central Nervous System. Oxford University Press. tr. 75. ISBN 978-0-19-022896-5.
↑  Scheggia D, Sannino S, Scattoni ML, Papaleo F (tháng 5 năm 2012). “COMT as a drug target for cognitive functions and dysfunctions”. CNS & Neurological Disorders Drug Targets. 11 (3): 209–21. doi:10.2174/187152712800672481. PMID 22483296.
↑  Diaz-Asper CM, Weinberger DR, Goldberg TE (tháng 1 năm 2006). “Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics”. NeuroRx. 3 (1): 97–105. doi:10.1016/j.nurx.2005.12.010. PMC 3593358. PMID 16490416.
↑  Schacht, Joseph P. (tháng 10 năm 2016). “COMT val158met moderation of dopaminergic drug effects on cognitive function: A critical review”. Pharmacogenomics Journal. 16 (5): 430–438. doi:10.1038/tpj.2016.43. PMC 5028240. PMID 27241058.
↑  Juarez B, Han MH (tháng 9 năm 2016). “Diversity of Dopaminergic Neural Circuits in Response to Drug Exposure”. Neuropsychopharmacology. 41 (10): 2424–46. doi:10.1038/npp.2016.32. PMC 4987841. PMID 26934955.
↑  Nissinen E biên tập (2010). Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors. Academic Press. tr. 34. ISBN 978-0-12-381327-5 – qua Google books.
↑  Chen J, Song J, Yuan P, Tian Q, Ji Y, Ren-Patterson R, Liu G, Sei Y, Weinberger DR (tháng 10 năm 2011). “Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: implications for drug development”. The Journal of Biological Chemistry. 286 (40): 34752–60. doi:10.1074/jbc.M111.262790. PMC 3186432. PMID 21846718. The cellular distribution of MB-COMT in cortical neurons remains unclear and the orientation of MB-COMT on the cellular membrane is controversial.
↑  Schott BH, Frischknecht R, Debska-Vielhaber G, John N, Behnisch G, Düzel E, Gundelfinger ED, Seidenbecher CI (2010). “Membrane-Bound Catechol-O-Methyl Transferase in Cortical Neurons and Glial Cells is Intracellularly Oriented”. Frontiers in Psychiatry. 1: 142. doi:10.3389/fpsyt.2010.00142. PMC 3059651. PMID 21423451. It has been a matter of debate whether in neural cells of the CNS the enzymatic domain of MB-COMT is oriented toward the cytoplasmic or the extracellular compartment.
↑  Golan DE, Tashjian AH (ngày 15 tháng 12 năm 2011). Principles of pharmacology (ấn bản thứ 3). Philadelphia: Wolters Kluwer Health. ISBN 978-1-60831-270-2. OCLC 705260923.
↑  Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silva P (2007). “Catechol-O-methyltransferase and its inhibitors in Parkinson's disease”. CNS Drug Reviews. 13 (3): 352–79. doi:10.1111/j.1527-3458.2007.00020.x. PMC 6494163. PMID 17894650.
↑  Jatana N, Apoorva N, Malik S, Sharma A, Latha N (tháng 1 năm 2013). “Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders”. Central Nervous System Agents in Medicinal Chemistry. 13 (3): 166–94. doi:10.2174/1871524913666140109113341. PMID 24450388. Two of the nitrocatechols, entacapone... and tolcapone... have been demonstrated to reduce the dose of L-DOPA required and also cause improvement in clinical symptoms, although tolcapone emerged to be more efficacious due to its greater bioavailability and a longer half-life when compared to entacapone. However, tolcapone is clinically restricted owing to its increased hepatotoxicity and other related digestive disorders.